Head-to-head evidence
Rongliflozin vs THR-1442
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: SGLT2 · full Type 2 Diabetes pipeline
Rongliflozin
Developed by Sunshine Lake Pharma
NCT05427682 · Phase 1 · completed
A non-randomized, open-label, parallel-group pharmacokinetic study of rongliflozin in 32 participants with normal or impaired liver function. With no randomization, no blinding, no comparator arm, and no results posted to the registry, this is weak evidence.
THR-1442
Developed by Newsoara Biopharma
NCT05369078 · Phase 1 · status unknown
This was a small, non-randomized, unblinded study in healthy volunteers with no placebo or comparator arm, designed only to characterize safety and drug levels. Results have not yet been posted.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Rongliflozin's landscape · THR-1442's landscape